Literature DB >> 16298078

Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

S A Lloyd1, C J Faherty, R J Smeyne.   

Abstract

Cocaine abuse is a significant problem in the United States, including its use by approximately 1% of pregnant women. Cocaine acts as an indirect agonist of dopamine at the dopamine transporter, resulting in the presence of excess dopamine in the synapse. Since synaptic dopamine can rapidly oxidize to form free radicals, it was hypothesized that exposure to this drug might produce damage in dopaminergic systems such as the substantia nigra pars compacta, damage to which is a hallmark of Parkinson's disease. To test this hypothesis we exposed mice both in utero and as adults to cocaine and examined its effects on the nigrostriatal system. We found that exposure to cocaine both in utero or as adults did not affect substantia nigra cell number, but did make these neurons more susceptible to the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We also found long-lasting changes in D2 receptor mRNA levels as well as changes in the monoamine transport system and several growth factors. This work suggests that use of cocaine might be a predisposing factor for development of Parkinson's disease in both adults exposed chronically as well as in individuals exposed prenatally.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298078     DOI: 10.1016/j.neuroscience.2005.09.035

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  Cocaine induces alterations in mitochondrial membrane potential and dual cell cycle arrest in rat c6 astroglioma cells.

Authors:  Ramesh B Badisa; Selina F Darling-Reed; Carl B Goodman
Journal:  Neurochem Res       Date:  2009-09-16       Impact factor: 3.996

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

3.  Susceptibility to a parkinsonian toxin varies during primate development.

Authors:  B A Morrow; R H Roth; D E Redmond; S Diano; J D Elsworth
Journal:  Exp Neurol       Date:  2012-02-14       Impact factor: 5.330

Review 4.  Endocrine-disrupting chemicals: associated disorders and mechanisms of action.

Authors:  Sam De Coster; Nicolas van Larebeke
Journal:  J Environ Public Health       Date:  2012-09-06

Review 5.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

6.  Cocaine selectively increases proliferation in the adult murine hippocampus.

Authors:  Steven A Lloyd; Zachary R Balest; Frank S Corotto; Richard J Smeyne
Journal:  Neurosci Lett       Date:  2010-09-15       Impact factor: 3.046

7.  Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.

Authors:  B A Morrow; R H Roth; D E Redmond; J D Elsworth
Journal:  Neuroscience       Date:  2011-06-01       Impact factor: 3.590

8.  Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

Authors:  G Muthian; V Mackey; J King; C G Charlton
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

9.  Developmental heptachlor exposure increases susceptibility of dopamine neurons to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in a gender-specific manner.

Authors:  Jason R Richardson; W Michael Caudle; Min Zheng Wang; E Danielle Dean; Kurt D Pennell; Gary W Miller
Journal:  Neurotoxicology       Date:  2008-06-05       Impact factor: 4.294

10.  Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice.

Authors:  Shankar Sadasivan; Brooks B Pond; Amar K Pani; Chunxu Qu; Yun Jiao; Richard J Smeyne
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.